Celera's Q4 Sales Fall 11 Percent on Lower Licensing Revenues | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Celera today reported that its fourth-quarter sales fell 11 percent as its licensing revenues declined sharply year over year.

The Alameda, Calif.-based molecular diagnostics firm, which announced separately that it will be acquired by Quest Diagnostics for $671 million, brought in total revenues of $34.9 million for the three-month period ended Dec. 25, compared to $39.2 million for Q4 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.